Pluri Inc. (PLUR)
NASDAQ: PLUR · Real-Time Price · USD
2.300
-0.080 (-3.36%)
Jun 10, 2026, 12:31 PM EDT - Market open
Pluri Revenue
Pluri had revenue of $167.00K in the quarter ending March 31, 2026, a decrease of -60.89%. This brings the company's revenue in the last twelve months to $1.08M, up 4.35% year-over-year. In the fiscal year ending June 30, 2025, Pluri had annual revenue of $1.34M with 309.82% growth.
Revenue (ttm)
$1.08M
Revenue Growth
+4.35%
P/S Ratio
23.80
Revenue / Employee
$7,599
Employees
142
Market Cap
24.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.34M | 1.01M | 309.82% |
| Jun 30, 2024 | 326.00K | 39.00K | 13.59% |
| Jun 30, 2023 | 287.00K | 53.00K | 22.65% |
| Jun 30, 2022 | 234.00K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | 23.00K | -31.00K | -57.41% |
| Jun 30, 2019 | 54.00K | 4.00K | 8.00% |
| Jun 30, 2018 | 50.00K | - | - |
| Jun 30, 2017 | - | - | - |
| Jun 30, 2016 | 2.85M | 2.47M | 651.19% |
| Jun 30, 2015 | 379.00K | - | - |
| Jun 30, 2014 | 379.00K | -300.00K | -44.18% |
| Jun 30, 2013 | 679.00K | -37.00K | -5.17% |
| Jun 30, 2012 | 716.00K | - | - |
| Jun 30, 2011 | - | - | - |
| Jun 30, 2010 | - | - | - |
| Jun 30, 2009 | - | - | - |
| Jun 30, 2008 | - | - | - |
| Jun 30, 2007 | - | - | - |
| Jun 30, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 26.55M |
| Barinthus Biotherapeutics | 14.97M |
| Palatin Technologies | 12.88M |
| Dyadic International | 3.81M |
| Allarity Therapeutics | 345.00K |
| Neuphoria Therapeutics | -13.27K |
PLUR News
- 8 days ago - Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing - GlobeNewsWire
- 2 months ago - Pluri announces additional $2.5M investment from Alejandro Weinstein - TheFly
- 4 months ago - Pluri secures global IP position with CNIPA for immune cell expansion - TheFly
- 4 months ago - Pluri completes first phase of program with Resbiomed Technologies OOD - TheFly
- 6 months ago - Pluri announces expansion of manufacturing agreement with Remedy Cell - TheFly
- 6 months ago - Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved - GlobeNewsWire
- 6 months ago - Pluri appoints Weinstein as Chairman of the Board of Directors - TheFly
- 7 months ago - Pluri announces launch of Cellav Health and Aesthetics - TheFly